Latest releases

Feb 14, 2019 ı Corporate Releases

Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder

Feb 5, 2019 ı Corporate Releases

Annual Report 2018 for H.Lundbeck A/S

View all releases

Join Lundbeck

Current open positions

Browse global vacancies

Q4 2018 financial results

Watch the investor presentation

 

Download the Q4 2018 release

Latest feature

February 2019:

 

Lundbeck takes part in a comprehensive initiative to understand the blood-brain barrier

 

Read more

Investor portal

DK

Modtag din invitation til årets generalforsamling elektronisk. Tilmeld din mail via investorportalen.

 

UK

Receive your invitation to this year’s AGM electronically. Sign-up your email via the Investor Portal.

 

Corporate film

play

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. 

 

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.